Scandinavian ChemoTech

"We are thrilled with the momentum we have seen as we move into the second quarter," said Mohan Frick, CEO. "Nearing our Q1 order volume in just one month is a testament to the hard work of our team and the trust our customers place in Tumor-Specific Electroporation (TSE)."

While the company is optimistic about the trajectory for Q2, the sales forecast for the remainder of the quarter is still uncertain. "While we are encouraged by this strong start, it's too early to project how the rest of the quarter will unfold," said Ann Ohlsson, Head of finance.